Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) Short Interest Down 51.0% in June

Posted by Francis Steltz on Jul 16th, 2026

Theriva Biologics, Inc. (NYSEAMERICAN:TOVX – Get Free Report) was the recipient of a large decrease in short interest in June. As of June 30th, there was short interest totaling 1,452,613 shares, a decrease of 51.0% from the June 15th total of 2,962,839 shares. Currently, 4.3% of the company’s shares are sold short. Based on an average daily trading volume, of 1,062,756 shares, the short-interest ratio is presently 1.4 days.

Wall Street Analyst Weigh In

Separately, Maxim Group upgraded shares of Theriva Biologics from a “hold” rating to a “buy” rating and set a $1.00 price objective for the company in a research note on Tuesday, March 31st. One investment analyst has rated the stock with a Buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $1.00.

Check Out Our Latest Report on TOVX

Theriva Biologics Stock Down 6.0%

Shares of TOVX stock traded down $0.01 on Thursday, reaching $0.23. 309,994 shares of the company were exchanged, compared to its average volume of 15,655,882. The company has a debt-to-equity ratio of 0.11, a current ratio of 1.63 and a quick ratio of 1.63. The company has a 50-day moving average of $0.28 and a 200-day moving average of $0.24. The company has a market cap of $7.71 million, a price-to-earnings ratio of -0.01 and a beta of 1.09. Theriva Biologics has a one year low of $0.16 and a one year high of $0.86.

Theriva Biologics (NYSEAMERICAN:TOVX – Get Free Report) last issued its earnings results on Tuesday, May 5th. The company reported ($0.05) EPS for the quarter. The company had revenue of $0.30 million during the quarter.

Institutional Investors Weigh In On Theriva Biologics

An institutional investor recently bought a new position in Theriva Biologics stock. Two Sigma Investments LP bought a new position in Theriva Biologics, Inc. (NYSEAMERICAN:TOVX – Free Report) during the third quarter, according to its most recent filing with the SEC. The firm bought 61,837 shares of the company’s stock, valued at approximately $25,000. Two Sigma Investments LP owned approximately 0.64% of Theriva Biologics as of its most recent SEC filing. Institutional investors and hedge funds own 6.17% of the company’s stock.

About Theriva Biologics

(Get Free Report)

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.